CEACAM5 and familial pancreatic carcinoma: One ongoing clinical trial is analysing the effect of CAR2Anti-CEA CAR-T cell infusion to the hepatic artery for patients with pancreatic cancer and CEA+ liver metastases that are resistant to standard therapy [37].